| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 3 data readout example | navenibart (STAR-0215) hereditary angioedema (HAE) | Phase 3 | — | Biologics | Rare Diseases | ||
Phase 3 data readout example | navenibart (STAR-0215) hereditary angioedema (HAE) | Phase 3 | — | Biologics | Rare Diseases | ||
Phase 3 data readout example | navenibart (STAR-0215) hereditary angioedema (HAE) | Phase 3 | — | Biologics | Rare Diseases |
Recent Updates
Recently added Catalysts
Astria Therapeutics, Inc.$12.58
+0.1 (+0.8%)
D 35Pipeline Score Overvalued Pharma · Clinical
Market Cap
718.13 M
EPS
-2.15
P/E Ratio
-
Value Trade
40.15 M
-1.8 %
Week
-2.56 %
1 Month
-0.08 %
3 Month
89.74 %
6 Month
-23.76 %
5 Year
-98.35 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
3.20 M
52 Week Range
3.56 - 13.29
% held by Insiders
12.34 %
% held by Institutions
79.39 %
Enterprise Value
590.19 M
Total Shares
56.41 M
Short %
9.16 %
Float Shares
45.70 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
D35
Pipeline Score $310M
Pipeline ValueOvervalued
Valuation Signal3
Drugs Scored0.4x
rNPV / MCap Top 47%
Micro Cap (rank 481 of 905)
Percentile RankAstria Therapeutics, Inc. faces pipeline headwinds (35/100), with $937M risk-adjusted pipeline value, led by navenibart in Hereditary Angioedema (HAE) (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| navenibart Small molecule | Hereditary Angioedema (HAE) | Phase 3 | NCT06842823 | 50% | $668M | ENROLLING BY_INVITATION | 290 | VERY_FAST | B (63) | Sep 1, 2027 | - | LOW Jun 5, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Navenibart | Hereditary Angioedema | Phase 1b/2 | 2025-06-16 | |||
Navenibart | Hereditary Angioedema | Phase 1b/2 | 2025-06-16 | |||
Navenibart | Hereditary Angioedema | Phase 1b/2 | 2025-06-16 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ATXS
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Astria Therapeutics, Inc. (ATXS) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
ATXS
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ATXS
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ATXS
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ATXS Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
ATXS Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
Competitive Position
How ATXS ranks across every disease it competes inCompetitive Position is a premium feature
See how ATXS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial